These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27203772)

  • 1. Nanoliposomal irinotecan in metastatic pancreatic cancer.
    Milosevic I; Drysdale H; Goldacre B;
    Lancet; 2016 May; 387(10032):1997. PubMed ID: 27203772
    [No Abstract]   [Full Text] [Related]  

  • 2. Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply.
    Chen LT; Wang-Gillam A; Von Hoff DD; Bayever E; Belanger B
    Lancet; 2016 May; 387(10032):1997. PubMed ID: 27203770
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
    Ur Rehman SS; Lim K; Wang-Gillam A
    Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy: NAPOLI-1: winning scoop for metastatic pancreatic cancer.
    Hutchinson L
    Nat Rev Clin Oncol; 2016 Jan; 13(1):2-3. PubMed ID: 26667974
    [No Abstract]   [Full Text] [Related]  

  • 6. Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability.
    Mondo EL; Noel MS; Katz AW; Schoeniger LO; Hezel AF
    J Clin Oncol; 2013 Jan; 31(3):e37-9. PubMed ID: 23233707
    [No Abstract]   [Full Text] [Related]  

  • 7. Gemcitabine-resistant pancreatic cancer: a second-line option.
    Oettle H; Lehmann T
    Lancet; 2016 Feb; 387(10018):507-508. PubMed ID: 26616909
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals.
    Bates SE; Fojo T
    Nat Rev Clin Oncol; 2016 Apr; 13(4):205-6. PubMed ID: 26902963
    [No Abstract]   [Full Text] [Related]  

  • 9. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
    Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
    Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting a response to FOLFIRINOX in pancreatic cancer.
    Nipp RD; Ryan DP
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26025325
    [No Abstract]   [Full Text] [Related]  

  • 11. Pancreatic ductal adenocarcinoma: metastatic disease.
    Muñoz Martín AJ; Adeva J; Martínez-Galán J; Reina JJ; Hidalgo M
    Clin Transl Oncol; 2017 Dec; 19(12):1423-1429. PubMed ID: 28623515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete pathological response after chemotherapy alone in a patient with pancreatic adenocarcinoma.
    Carbonell S; Espinosa J; Zarco A; de-Madaria E; de la Hoz J; Yuste A; Payá A; Lluís F
    Pancreas; 2012 May; 41(4):657-9. PubMed ID: 22504386
    [No Abstract]   [Full Text] [Related]  

  • 13. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.
    Sonbol MB; Firwana B; Wang Z; Almader-Douglas D; Borad MJ; Makhoul I; Ramanathan RK; Ahn DH; Bekaii-Saab T
    Cancer; 2017 Dec; 123(23):4680-4686. PubMed ID: 28817187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
    Yanagimoto H; Satoi S; Sho M; Akahori T; Yamamoto T; Hirooka S; Yamaki S; Kotsuka M; Ryota H; Kinoshita S; Nishiwada S; Nagai M; Ikeda N; Tsuta K; Nakajima Y; Kon M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):35-41. PubMed ID: 26645403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
    Tinchon C; Hubmann E; Pichler A; Keil F; Pichler M; Rabl H; Uggowitzer M; Jilek K; Leitner G; Bauernhofer T
    Acta Oncol; 2013 Aug; 52(6):1231-3. PubMed ID: 23445338
    [No Abstract]   [Full Text] [Related]  

  • 16. Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma.
    Bisht S; Brossart P; Feldmann G
    Oncol Res Treat; 2018; 41(10):590-594. PubMed ID: 30286472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course.
    Boeck S; Mehraein Y; Ormanns S; Kruger S; Westphalen CB; Haas M; Jung A; Kirchner T; Heinemann V
    Ann Oncol; 2017 Feb; 28(2):438-439. PubMed ID: 27803004
    [No Abstract]   [Full Text] [Related]  

  • 18. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.
    Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R
    Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [nab-Paclitaxel as new therapeutic option for pancreatic cancer].
    Michl P
    Z Gastroenterol; 2013 Nov; 51(11):1329-30. PubMed ID: 24243574
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic and predictive markers in pancreatic adenocarcinoma.
    Le N; Sund M; Vinci A;
    Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.